Vaccine Composition Comprising Alpha-Galactosylceramide as an Adjuvant For Intranasal Administration

摘要

The present invention related to a vaccine composition comprising alpha-galactosylceramide (alphaGalCer) as an adjuvant for the intranasal administration. The present inventors administered alphaGalCer together with a tumor cell antigen or a virus antigen to the nasal cavity of a mouse and then confirmed that the alphaGalCer effectively induced not only humoral immunity but also cell-mediated immunity. Thus, the alphaGalCer can be effectively used as an adjuvant for a vaccine by the intranasal administration for the prevention and treatment of virus infection and cancer.